Summary:
Evaluate the Efficacy, Safety, and Tolerability of the drug in treating patients with Moderate to Severe Persistent Asthma with Type 2 Inflammation
- Be currently receiving treatment with medium to high dose inhaled corticosteroids (ICS) in combination with at least 1 additional reliever/controller for at least 90 days prior to the Screening Visit with a stable dose of ICS at least 28 days prior to the Screening Visit.
- Have experienced an asthma exacerbation at least once in the past 12 months.
Qualified Participants May Receive:
$100 Per completed in person visit.